GlassScriptPhysician profile
Ashlee Paknis
NPI 1144877747
$8,065.89
in general payments reported to CMS, 2019-2025
27 companies · $3,228 in 2025
The $3,228 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $38.84 · 2022: $1,042 · 2023: $1,852 · 2024: $1,905 · 2025: $3,228.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,618 · Education: $367.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,617.56 |
| Education | $367.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,319.00 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $821.39 | 2022-2025 | Absorica Ld, Winlevi, Ilumya |
| Abbvie INC. | $745.98 | 2021-2025 | |
| Ucb, INC. | $741.83 | 2024-2025 | Bimzelx |
| Arcutis Biotherapeutics, INC. | $737.74 | 2023-2025 | Zoryve |
| Janssen Biotech, INC. | $508.03 | 2022-2025 | Tremfya, Stelara, Remicade |
| Regeneron Healthcare Solutions, INC. | $457.62 | 2022-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $398.90 | 2022-2025 | |
| Incyte Corporation | $294.34 | 2022-2025 | Opzelura |
| Galderma Laboratories, L.P. | $293.46 | 2022-2025 | Nemluvio, Aklief |
| Dermavant Sciences, INC. | $240.40 | 2023-2024 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $212.38 | 2024-2025 | Cabtreo, Jublia, Arazlo |
| Lilly USA, LLC | $205.55 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Pfizer INC. | $181.77 | 2022-2025 | |
| Almirall LLC | $181.56 | 2022-2025 | Seysara, Klisyri |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $138.07 | 2023-2024 | Sotyktu |
| Amgen INC. | $130.77 | 2022-2024 | Otezla |
| Sanofi-Aventis U.S. LLC | $99.00 | 2023 | |
| Leo Pharma INC. | $79.29 | 2024-2025 | Adbry, Anzupgo |
| Mayne Pharma Commercial LLC | $66.34 | 2022-2025 | |
| Ani Pharmaceuticals, INC. | $45.74 | 2025 | Oxistat, Veregen |
| Botanix Sb INC | $45.23 | 2025 | Sofdra |
| Lnhc, INC | $33.17 | 2025 | Zelsuvmi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.79 | 2025 | Spevigo |
| Epi Health, LLC | $25.28 | 2022 | |
| Mallinckrodt Hospital Products INC. | $18.25 | 2024 | Acthar |
| Organon LLC | $16.01 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashlee Paknis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.